NEWARK, Calif.--(BUSINESS WIRE)--Nov. 20, 2018--
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company
developing next-generation neuromodulators for use in treating aesthetic
and therapeutic conditions, today announced that the Company will
participate in two upcoming investor conferences.
President and Chief Executive Officer, Dan Browne, is scheduled to
participate in a fireside discussion at the Evercore ISI, HealthCONx in
Boston, MA on Tuesday, November 27 at 4:15pm ET.
President and Chief Executive Officer, Dan Browne, is also scheduled to
participate in a fireside discussion at the Piper Jaffray 30th Annual
Healthcare Conference in New York, NY on Wednesday, November 28 at
Interested parties can access the live audio webcasts for both
conferences from the Investor Relations section of the company's website
The webcast replays will be available after the conclusion of the live
fireside discussions for approximately 30 days.
About Revance Therapeutics, Inc.
Revance Therapeutics is an emerging Silicon Valley biotechnology leader
developing neuromodulators for the treatment of aesthetic and
therapeutic conditions. Revance uses a unique proprietary, stabilizing
excipient peptide technology to create novel, differentiated therapies.
The company’s lead compound, DaxibotulinumtoxinA for Injection (RT002),
is in clinical development for a broad range of aesthetic and
therapeutic indications, including glabellar lines, cervical dystonia,
plantar fasciitis, upper limb spasticity and chronic migraine. RT002 has
the potential to be the first long-acting neuromodulator. The company is
advancing a robust pipeline of injectable and topical formulations of
DaxibotulinumtoxinA. More information on Revance may be found at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181120005473/en/
Source: Revance Therapeutics, Inc.
Revance Therapeutics, Inc.: